Skip to Content

Treximet Approval History

FDA Approved: Yes (First approved April 15, 2008)
Brand name: Treximet
Generic name: sumatriptan succinate and naproxen sodium
Dosage form: Tablets
Previous Name: Trexima
Company: Currax Pharmaceuticals LLC
Treatment for: Migraine

Treximet is a combination of sumatriptan (a migraine-specific triptan) and naproxen (an anti-inflammatory pain reliever) in a single tablet for the acute treatment of migraine.

Development History and FDA Approval Process for Treximet

DateArticle
May 15, 2015Approval FDA Approves Treximet (sumatriptan and naproxen sodium) for Migraine in Pediatric Patients
Apr 16, 2008Approval Treximet (sumatriptan and naproxen sodium) Tablets Approved by FDAfor Acute Treatment of Migraine
Jan 16, 2008Pozen Submits Human Lymphocyte Study for Treximet (Formerly Known as Trexima)
Nov  1, 2007Pozen Announces Trexima (Sumatriptan Succinate and Naproxen Sodium) Amended Response Accepted for Review by FDA
Oct 15, 2007Pozen Submits Response to Approvable Letter for Trexima
Oct  5, 2007Pozen Plans to Submit Response to Approvable Letter For Trexima Within the Next Ten Days
Aug  2, 2007FDA Issues Second Approvable Letter for Trexima
Mar 22, 2007Pozen Announces Trexima (Sumatriptan Succinate and Naproxen Sodium) Amended Response Accepted for Review by FDA
Dec 13, 2006Pozen Expects to Submit Revised Response to Trexima Approvable Letter by Year End
Nov  9, 2006Pozen Submits Full Response to FDA Approvable Letter For Trexima
Jul 31, 2006Pozen to Submit Full Response to Trexima Approvable Letter During the Fourth Quarter
Jun  9, 2006Pozen Inc. and GlaxoSmithKline Report Receipt of Approvable Letter for Investigational Migraine Treatment
Oct 11, 2005GlaxoSmithKline and POZEN Announce Trexima (Sumatriptan Succinate and Naproxen Sodium) New Drug Application Accepted for Review by FDA
Aug  8, 2005POZEN Submits New Drug Application for Trexima (Sumatriptan Succinate and Naproxen Sodium) for the Acute Treatment of Migraine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide